A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

GSK plans to depart the biotechnology industry’s largest trade ... after Republicans took control of the White House and ...

The upgraded manufacturing campus will be equipped to crank out commercial drugs and vaccines plus house an R&D pilot plant to manufacture medicines for clinical trials. GSK plans to add about 200 ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

GSK asserts that Moderna's use of LNPs to deliver ... and move my position to “house money” status. Long term, I still intend on trading MRNA and will build a core position for a long-term ...

The future facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. As a result of this investment, GSK will double the size of its facility and ...